Ionis director awarded 3,399 RSUs in stock grant

HANTSON LUDWIG reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

HANTSON LUDWIG reported acquisition or exercise transactions in this Form 4 filing.

Ionis Pharmaceuticals director Ludwig Hantson received a grant of 3,399 Restricted Stock Units on July 15, 2026 under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Each RSU is a contingent right to one share of common stock or its cash value, vesting in three equal annual installments from July 15, 2027 and fully vesting on July 15, 2029. As of the grant date, 0 RSUs were vested and he holds 3,399 RSUs in total.

Insider Trade Summary

Grant/Award: 3,399 shares

Grant/Award 1 txn

Insider HANTSON LUDWIG

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit F1, F2	3,399	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 3,399 contracts (Direct)

Footnotes (2)

1. F1. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
2. F2. Grant on July 15, 2026 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in three equal annual installments, the first installment vesting on July 15, 2027. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 15, 2029. The RSU is vested as to 0 shares on July 15, 2026.

Key Figures

Restricted Stock Units granted: 3,399 units Underlying common shares per RSU: 1 share per unit Vesting installments: 3 annual installments +3 more

6 metrics

Restricted Stock Units granted 3,399 units Grant to director Ludwig Hantson on July 15, 2026

Underlying common shares per RSU 1 share per unit Each RSU is a contingent right to one share of Ionis common stock

Vesting installments 3 annual installments RSUs vest in three equal annual installments starting July 15, 2027

Full vesting date July 15, 2029 RSUs shall be fully vested on July 15, 2029

RSUs vested at grant 0 units RSUs are vested as to 0 shares on July 15, 2026

Total RSUs after grant 3,399 units Total restricted stock units held directly following the reported award

Key Terms

Restricted Stock Unit, contingent right, Amended and Restated 2002 Non-Employee Directors' Stock Option Plan

3 terms

Restricted Stock Unit financial

"Grant on July 15, 2026 to reporting person of Restricted Stock Unit Award"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"Each Restricted Stock Unit represents a contingent right to receive one share"

Amended and Restated 2002 Non-Employee Directors' Stock Option Plan financial

"under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ionis Pharmaceuticals (IONS) report for Ludwig Hantson?

Ionis reported that director Ludwig Hantson received a grant of 3,399 Restricted Stock Units (RSUs) on July 15, 2026. The award was made under the company’s Amended and Restated 2002 Non-Employee Directors' Stock Option Plan and is payable in stock or cash upon vesting.

How many Restricted Stock Units did Ludwig Hantson receive in the IONS Form 4 filing?

Ludwig Hantson received 3,399 Restricted Stock Units from Ionis Pharmaceuticals. These RSUs correspond to 3,399 underlying shares of Ionis common stock, subject to vesting conditions, and result in total direct holdings of 3,399 RSUs immediately after the grant.

What is the vesting schedule for Ludwig Hantson's 3,399 Ionis (IONS) Restricted Stock Units?

The 3,399 RSUs vest in three equal annual installments beginning July 15, 2027. The award becomes fully vested on July 15, 2029, with 0 RSUs vested as of the July 15, 2026 grant date, according to the plan’s terms.

What does each Restricted Stock Unit represent in Ludwig Hantson's Ionis (IONS) award?

Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock or its equivalent cash value. Upon vesting, the RSUs will be paid out in whole shares or cash, as determined by Ionis Pharmaceuticals.

Under which equity plan were Ludwig Hantson's Ionis (IONS) RSUs granted?

The RSUs were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. This plan provides equity-based compensation to non-employee directors, including Restricted Stock Unit awards like Hantson’s grant.

How many Restricted Stock Units does Ludwig Hantson hold after this Ionis (IONS) grant?

Following the reported transaction, Ludwig Hantson holds 3,399 Restricted Stock Units. As of the July 15, 2026 grant date, the RSUs are vested as to 0 shares, with vesting beginning in 2027 and completing in 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 05:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HANTSON LUDWIG

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CALIFORNIA 92010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0.0(1)	07/15/2026		A		3,399		(2)	(2)	Common Stock	3,399	$0.0	3,399	D

Explanation of Responses:

1. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

2. Grant on July 15, 2026 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in three equal annual installments, the first installment vesting on July 15, 2027. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 15, 2029. The RSU is vested as to 0 shares on July 15, 2026.

	By: Patrick R. O'Neil, attorney-in-fact For: Ludwig Hantson	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)